Macrophages get a CAR | Nature Reviews Cancer Skip to main content Thank you for visiting
nature.com. You are using a browser version with limited support for CSS. To obtain the best …

Immunotherapy startups look to engineer macrophages to fight solid tumors. Full Text:
Author (s): Elie Dolgin 1 Author Affiliations:(1) Somerville, USA The scientific founders of …

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic
malignancies, but its application to solid tumors has been challenging,,–. Given the unique …

Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated profound results
in hematologic malignancies but clinical efficacy in the solid tumor setting has not been …

Expressing chimeric antigen receptors (CARs) in macrophages has led to promising results
in preclinical and clinical work. Now, induced pluripotent stem cells have been combined …

Cellular immunotherapies represent a promising approach for the treatment of cancer.
Engineered adoptive cell therapies redirect and augment a leukocyte's inherent ability to …

Recent understanding of the role and contribution of immune cells in disease onset and
progression has pioneered the field of immunotherapies. Use of genetic engineering to …

A growing number of approaches to treating cancer, including antibodies, vaccines, and cell
therapy, harness the immune system to seek and destroy cancer cells (-). Antibody-mediated …

Preliminary results and emerging data have shown that lipid droplet high (LDhi)
immunosuppressive cells accumulate in tumour tissues. By tracking and phenotypic profiling …

Cancer immunotherapy has revolutionized the paradigm for the clinical management of
cancer. While FDA-approved cancer immunotherapies thus far mainly exploit the adaptive …